← All trials
NCT05906251
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2023
- Primary completion
- Aug 31, 2028
- Completion date
- Aug 31, 2028
- First posted
- Jun 15, 2023
- Last posted
- Nov 15, 2023
- Enrollment
- 2
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sarepta TherapeuticsLead sponsor
- Sarepta TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.